Antiemetics in children receiving chemotherapy

Support Care Cancer. 2005 Feb;13(2):129-31. doi: 10.1007/s00520-004-0702-6. Epub 2004 Nov 5.


Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not been identified. Combinations of a 5-HT3 antagonist and dexamethasone show increased efficacy with respect to 5-HT3 antagonists alone. All pediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.

Publication types

  • Review

MeSH terms

  • Antiemetics / therapeutic use*
  • Antineoplastic Agents / adverse effects*
  • Child
  • Dexamethasone / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Serotonin 5-HT3 Receptor Antagonists
  • Vomiting / chemically induced*
  • Vomiting / prevention & control*


  • Antiemetics
  • Antineoplastic Agents
  • Serotonin 5-HT3 Receptor Antagonists
  • Dexamethasone